Gujarat Themis Biosyn Ltd


BSE: 506879 | NSE: GUJTHEMIS | ISIN: INE942C01029 
Market Cap: [Rs.Cr.] 28 | Face Value: [Rs.] 5
Industry: Pharmaceuticals - Indian - Bulk Drugs

 Discuss this stock

Director's Report

Directors

To,

The Members,

Your Directors have pleasure in presenting herewith the 30th Annual Report togetherwith the Audited Accounts of the Company for the Financial Year ended 31st March, 2011

FINANCIAL RESULTS

(Rs. in Lakhs)
Year ended 31.03.2011 Year ended 31.03.2010
Total Income 1369.60 1563.59
Operating Profit / (Loss) (89.62) 142.54
Interest and Finance charge 125.54 159.80
Profit / (Loss) before depreciation, prior period adjustments & tax (215.16) (17.26)
Profit./ (loss) after depreciation and tax (326.53) (103.06)
Income tax for earlier year 1.15 4.74
Fringe Benefit Tax for earlier year 0.55
Net Profit/(Loss) after tax (327.68) (108.35)
Surplus/(Deficit) brought forward (2463.09) (2354.74)
Surplus / (Deficit) carried forward to Balance Sheet (2790.77) (2463.09)

OPERATIONS

Your Company’s operations during the year under review have declined due to fireaccident occurred in your factory at Vapi on 9th December, 2010 affecting and damaging asection of plant, building, various equipments etc. Further due to less order on Job work,company could not achieve the production capacity.

Your Company’s sales for the year ending 31st March, 2011 is Rs.0.40 Lacs(previous year Rs.2.28 lacs) and conversion charges for job work is Rs.1337.81 lacs(previous year Rs.1545.70 Lacs ). The operating loss for the year is Rs.89.62 lacs ascompared to operating profit of Rs. 142.54 lacs for the previous year. The net lossrecorded by the Company for the year is Rs. 327.68 lacs as compared to net loss ofRs.108.35 lacs in the previous year.

BIFR

Your Company became "Sick Company" as defined under Sec 3 (1) (o) of the SickIndustrial Companies (Special provision) Act 1985, and in accordance with the provisionsof section 15 (I) of the said Act and registered with BIFR on 5/11/2007 under referenceNo.67/2007.

Based on the direction by BIFR the Revised Draft Rehabilitation Scheme has beenprepared by Union Bank of India (Operating Agency) in consultation with the promoters andother involved agencies and submitted to BIFR for their consideration.

Your Company is hopeful of working out an acceptable revival strategy and turn aroundthe performance of the Company within a reasonable time with technical and financialsupport of new co-promoters.

MANAGEMENT DISCUSSIONS AND ANALYSIS

1. Industry Structure & Developments

India has been making rapid strides in the field of Bulk Drugs and majority of thesedrugs required in India are manufactured in India. India also happens to be a majorexporter of bulk drugs all over the globe, particularly to Europe and US markets.

2. Opportunity, Threats, Outlook, Risk and Concerns

The Indian fermentation industry does not have a level playing field as compared toChina. The energy cost, labour cost and raw material cost are much lower in China,therefore the Company finds itself in a very difficult situation.

3. Segment-wise or Product-wise Performance

Your Company is engaged in manufacturing activities on Job Work basis. Your company isalso on look out for new products to support its activities and fixed costs.

4. Internal Control Systems and their adequacy.

The Company has adequate internal control procedures which commensurate with its sizeand nature of business. The internal control procedures and systems ensure efficient useand protection of resources and compliance with the policies, procedures and statutes.

5. Material Developments in Human Resources and Industrial Relations

Fermentation industry is a high technology Industry. Continues efforts are being madein training the employees through In-house training programs to suit the Company’srequirements. Industrial Relations have been generally cordial and healthy.

DIRECTORS

In terms of Article of Association of the Company as well as the requirement of theCompanies Act, 1956, Dr. Sachin D Patel, Mr. J.K. Cha and Mr. Vijay Agarwal retires byrotation at the ensuing Annual General Meeting and being eligible, offer themselves forre-appointment.

Mr. Rajneesh Anand was re-appointed as Managing Director of the Company for a period ofthree years with effect from 1st February, 2011. The Board places on record their sincereappreciation for the useful contribution made by Mr. Rajneesh Anand as the ManagingDirector.

INDUSTRIAL RELATIONS

Relations between the Management and the workers generally remained cordial andpeaceful.

AUDITORS

Messrs Khandelwal Jain & Co., Chartered Accountants, Statutory Auditors of theCompany retires at the conclusion of the forthcoming Annual General Meeting and beingeligible, offers themselves for re-appointment.

The Auditors have furnished to the Company the requisite Certificate under Section 224(1B) of the Companies Act, 1956.

INTERNAL AUDITOR

The Company has appointed M/s Gopalkrishnan Aiyer & Co., Chartered Accountants asInternal Auditors of the Company.

COST AUDITORS

The Company being Sick Unit and Registered with BIFR and presently the Company isengaged in manufacturing activities on Job Work basis.

Based on the said reason, the company making an application to Central Government forexemption from Cost Audit of the Record of the Company for the financial year 2010-11 u/s233 of the Companies Act, 1956.

PARTICULARS OF EMPLOYEES

No employees of the Company are drawing salary in excess of the limits specified undersection 217(2A) of the Companies Act, 1956 read with the Companies (Particulars ofEmployees) Rules, 1975.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

Information on conservation of energy and technology absorption etc. as required to bedisclosed in terms of Section 217(1) (e) of the Companies Act, 1956 read with theCompanies (Disclosure of Particulars in the Report of the Directors) Rules, 1988, aregiven in Annexure "A" to the Director’s Report.

CORPORATE GOVERNANCE

Report of Directors on compliance of conditions on Corporate Governance as specified inClause 49 of the Listing Agreement together with certificate issued by the PracticingCompany Secretary thereon attached to this Report.

DIRECTORS’ RESPONSIBILITY

Pursuant to Section 217(2AA) of the Companies Act, 1956 the Directors confirm that:

i) In the preparation of the Annual Accounts, the applicable accounting standards havebeen followed.

ii) The Directors have selected such accounting policies and applied them consistentlyand made judgments and estimates that are reasonable and prudent so as to give a true andfair view of the state of affairs of the Company at the end of the financial year and ofthe profit or loss of the Company for the financial year under consideration.

iii) The Directors have taken proper and sufficient care of the maintenance of adequateaccounting records in accordance with the provision of this act for safeguarding theassets of the Company and for preventing and detecting fraud and other irregularities.

iv) The Directors have prepared the annual accounts on a going concern basis.

AUDITORS’ OBSERVATIONS & COMMENTS

As regards remarks in the Auditors’ Report, the notes wherever referred to, areself-explanatory.

ACKNOWLEDGMENT

Your Directors have pleasure to place on record their sincere appreciation for thecontinued co-operation, support extended to the Company by Financial Institutions, UnionBank of India, all the Employees, Yuhan Corporation, the State Government of Gujarat,Dept. of Chemical & Petrochemical and various other Government authorities.

For and on behalf of the Board of Directors
RAJNEESH ANAND DR. SACHIN D. PATEL
Managing Director Director
Place : Mumbai
Date : 26th August, 2011

‘ANNEXURE A’ TO THE DIRECTORS REPORT

INFORMATION AS PER SECTION 217 (1) (e) READ WITH COMPANIES (DISCLOSURE OF PARTICULARSIN THE REPORT OF BOARD OF DIRECTORS) RULES, 1988 AND FORMING PART OF THE DIRECTORS'REPORT.

CONSERVATION OF ENERGY

(a) Energy conservation measures taken: -

During the year under review, all possible efforts were made to ensure optimumconservation of electricity and fuel at the plant.

(b) Additional investments and proposals, if any, being implemented for reduction ofconsumption of energy: -

The Company has introduced improved operational methods, improved maintenance systemsand rationalisation to bring about a saving in power consumption.

(c) Impact of measures at (a) and (b) above for reduction of energy consumption andconsequent impact on the cost of production of goods: -The adoption of energy conservationmeasures stated above is expected to help in saving to the Company on fuel and energycost.

(d) The total energy consumption per unit of production as per Form A of the Annexureto the Rules in respect of Industries specified in the Schedule thereto: -

The Company has invested substantial amount in the Plant and equipment to reduce energyConsumption and the Company will continue in its efforts to improve methods of energyconservation and utilisation.

FORM - A

Form for disclosure of Particulars with respect to Conservation of Energy

A POWER AND FUEL CONSUMPTION

2010-2011 2009-2010
1. Electricity :
a) Purchase :
Units 8685390 9636840
Total Amount 53391598 60143017
Rate/Unit (Rs.) 6.15 6.24
b) Own Generation :
Through diesel / LDO Generators (KwH) 116760 60824
Diesel / LDO Consumed (Liters) 51858 34396
Units / Liter of Diesel /LDO (KwH) 2.25 1.77
Total Amount (Rs.) 2162850 1224783
Cost / Unit ( Rs. / KwH) 18.52 20.14
2. Furnace Oil :
Quantity (Liters) 315167 301628
Total Amount (Rs) 8281905 7019567
Average Rate (Rs./Liter) 26.28 23.27
3. Coal / Lignite :
Quantity (Kgs) 7461990 7198000
Total Amount (Rs.) 37275691 32786997
Rate / Kgs (Rs.) 5.00 4.56

B. CONSUMPTION PER MT OF FINISHED GOODS PRODUCED *

2010-2011 2009-2010
Electricity per MT (Rs) 442790 386720
Furnace Oil Per MT (Rs) 68684 45136
Diesel /LDO Per MT (Rs) 17937 7875
Coal / Lignite Per MT (Rs) 309137 210820

* Figures are not comparable as mix of two products were produced and use ofsubstitute, also the per MT cost has been calculated excluding the finished goods used forcaptive consumption.

TECHNOLOGY ABSORPTION

Efforts made in technology absorption as per Form-B of the Annexure to the Rules:

FORM B

Form for disclosure of Particulars with respect to absorption

1 Research & Development ( R & D)

(a) Specific areas in which R & D carried out by the Company:

Since the company is currently in the Job work business, the company works on thedevelopment of processes and strains to improve productivity to increase the income/reduce losses.

(b) Benefits derived as a result of the above R & D:

The R & D activities of the Company have resulted in improved productivity andquality of the product, better yields and recoveries leading to cost containment.

(b) Future Plan of action:

The Research activity will continue to concentrate on new product, development ofproducts which the company will identify in future, process improvement and development.The Company is working aggressively to scale up new product.

(c) Expenditure on R & D:

(Rs. in Lakhs)
i. Capital Nil
ii. Recurring 1.66
iii. Total 1.66
iv. Total R&D Expenses as per percentage of total turnover 0.12%

2 Technology Absorption, Adaptation and Innovation:

(a) Efforts in brief, made towards technology absorption, adaptation and innovation:

The Company has taken steps to increase the yields and productivity to bring down thecost of operation.

(b) Benefits derived as a result of the above efforts:

- Reduction of operation cost.

- Improvement in product quality.

3. Activities related to exports, initiatives taken to increase exports,development of new export markets for products and services and export plan:

The company is in the job work business area only, however the product made by thecompany is used by the principals for manufacture of down stream API which is widelyexported. This will help the country to gain good foreign exchange. Our Principals earlierwere also importing the products manufactured by us from China. Thus our activity in a wayis also helping the country to save foreign exchange.

Total foreign exchange used and earned (Rs. In lakhs)
- Total foreign exchange earned NIL
- Total foreign exchange spent NIL

 

For and on behalf of the Board of Directors
RAJNEESH ANAND DR. SACHIN D. PATEL
Managing Director Director
Place : Mumbai
Date : 26th August, 2011

ANNEXURE ‘B’ TO THE DIRECTORS REPORT

REPORT ON CORPORATE GOVERNANCE

To,

The Members,

The Directors of the Company are pleased to present report on Corporate Governance forthe financial year ended 31st March, 2011.

PHILOSOPHY ON CODE OF GOVERNANCE

The philosophy underlying Corporate Governance seeks to create a system of "Checksand Balances" based on transparency, ensuring integrity, clarity and consistency inthe dealing of the Company with all its stakeholders. Good governance ensures that aCompany follows the best corporate practices. Implementation of good governance indicatesnot only the compliance of the laws and regulations of the land but also indicates thevalues, practices and culture of your organisation.

BOARD OF DIRECTORS

(A) Composition of the Board

The Company’s Board comprises an optimum combination of Executive andNon-Executive Directors in conformity with the provisions of the listing agreement onCorporate Governance. The Company also has the optimum number of Independent Directors inaccordance with the criteria given in Clause 49 of the listing agreement. TheNon-Executive Directors brings an external and wider perspective confirming therewith indepth business deliberations and decisions advantage. The Board represents an optimum mixof professionals, knowledge and expertise.

The Managing Director subject to the superintendents and direction of the Board ofDirectors manages the business of the Company. Details of Board of Directors and theirdirectorship/membership in committees of other companies (excluding Private Limited andForeign Companies) are as under:

Name of the Director Category Number of other directorships Committee Memberships
Chairman Member
Dr. Dinesh S. Patel Non executive Promoter Director 3 1
Dr. Sachin Dinesh Patel Non executive & Promoter Director 2 1
Mr. A. B Shah (Nominee of GIIC) Non executive & Independent 4 2
Mr. J. K. Cha Non executive Representative of Yuhan Corpn.
Mr. S. C. Kim Non executive Representative of Yuhan Corpn.
Mr J. H. Choi Non executive Representative of Yuhan Corpn.
Mr. S.S. Lee Non executive Representative of Yuhan Corpn.
Mr Vijay Agarwal Non executive & Independent 7 4
Mr Hinesh Doshi Non executive & Independent
Mr. Rajneesh Anand (Managing Director) Executive 1 1
Ms. Dharmishta N Raval Non executive & Independent
Mr. Subhash C Kaushik Non executive & Promoter Diector 1

(B) Details of attendance of the directors at the Board Meetings held in Financial Year2010-11 and at the last Annual General Meeting.

Name of the Director Number of Board Meetings held during F.Y. 2010-11 while holding the Office. Number of Board Meetings attended while holding the Office. Attendance at last Annual General Meeting.
Dr. Dinesh Patel 4 4 Yes
Dr. Sachin Dinesh Patel 4 4 Yes
Mr. A.B Shah (Nominee of GIIC) 4
Mr. J. K. Cha 4
Mr. S.S Lee 4
Mr. J. H. Choi 4
M. S.C Kim 4
Mr.Rajneesh Anand (Managing Director) 4 4 Yes
Mr. Vijay Agarwal 4 3
Mr. Hinesh Doshi 4 3
Ms. Dharmishta N. Raval 4 2
Mr. Subhash C Kaushik 3 1

The Board meetings are generally held in Mumbai. During the financial year 2010-11,Four meetings of the Board of Directors were held on 21st May, 2010, 31st July 2010, 111hNovember 2010 and 31st January 2011.

(C) Role of Independent Directors

The Independent Director's play an important role in bringing deliberation in BoardMeeting and guide the company with their wide experience in Accountancy, Finance, Taxationand Legal Fields.

(D) Board Meetings

The Meetings of the Board of Director's are held at regular intervals of not more thanfour months in Mumbai or at other places in India as per the convenience of the Directors.These are generally scheduled well in advance. The provisions of the Companies Act, 1956and those under Clause 49 of the Listing Agreement have been followed. The Board meets atleast once a Quarter to review Performance and Financial Results. All the major decisionsare taken at the Board meeting wherein directors are provided with all materialinformation. Senior Executives of the Company are invited to attend the board meeting andprovide clarifications as and when required.

The last Annual General Meeting of the Company was held on 28th September, 2010.

AUDIT COMMITTEE

Pursuant to provisions of Section 292A and Clause 49 of the Listing Agreement, theAudit Committee was formed on 27th June, 2001. The terms of reference and powers ofcommittee are in compliance with the provisions of clause 49 of the listing agreement oncorporate governance and Section 292A of the Companies Act, 1956. The Committee alsoreviews Reports of the Statutory Auditors along with the comments and action taken. SeniorExecutives are invited to attend the meeting of the Audit Committee as and when consideredappropriate. The head of Finance function regularly attends the Meeting of the AuditCommittee.

The Audit Committee consists of Mr. Vijay Agarwal – Chairman, Mr.Rajneesh Anand,Dr. Sachin D. Patel and Mr. Hinesh Doshi (upto 30th October, 2010). The Committee met fourtimes during the Financial Year 2010-11. The dates of Audit Committee meetings held duringFinancial Year 2010-11 are 21st May, 2010, 31st July 2010, 11th November, 2010 and 31stJanuary 2011 and most of the members were present at all the meetings.

REMUNERATION COMMITTEE

The Remuneration Committee of the Directors of the Company comprised of Dr. DineshPatel – Chairman, Mr. Vijay Agarwal and Dr. Sachin D. Patel.

Remuneration of Directors

Mr. Rajneesh Anand, the Managing Director is the only Executive Director in the Board.The Board of Directors of the Company takes all the decisions regarding appointment andpayment of remuneration to the Directors (including Managing Director) as per therecommendation of the Remuneration Committee.

The Company is paying managerial remuneration to the Managing Director only. Thedetails of such remuneration are given herewith.

The remuneration payable to Mr. Rajneesh Anand, Managing Director of the Company asspecified hereunder, is pursuant to provisions of Section 269, Schedule XIII and otherapplicable provisions of the Companies Act, 1956.

Details of remuneration paid to the Managing Director for year 2010-11 is as under:

Particulars Amount (in Rs.) (2010 – 11)
Salary 3,00,000/-
Gratuity
Leave Salary
LTA, Medical & Other benefits
Total 3,00,000/-

The Company has not paid any commission to the Managing Director.

In the year 2010-2011, the Company has not paid any sitting fees to the Directors.

SHARE TRANSFER AND INVESTORS GRIEVANCE COMMITTEE

The Share Transfer Committee was formed on 26th July, 2000 by the Board of Directors ofthe Company and had delegated the authority to approve transfer of shares and to attendother share transactions including transmission, transposition, split, consolidation andissue of duplicate share certificate so as to expedite the process relating thereto.During the financial year 2010-11, the Board of Directors has renamed the committee asShare Transfer & Investors Grievance Committee to look into the grievances ofinvestors in addition to approval of transfer of shares. The present members of ShareTransfer & Investors Grievance Committee are Mr. Rajneesh Anand – Chairman, Dr.Sachin Dinesh Patel & Mr.Vijay Agarwal .

The committee met 10 times during the Financial Year 2010-11. For some periods therewere no share transfers, therefore the share transfer committee meetings were not held.The Minutes of the Share Transfer Committee were laid before the Board of Directors forrecord. All the valid applications for share transfer received during the year 2010-11have been approved. During the year 2010-11, Company has received complaints fromShareholders and all the complaints were resolved and no complaint is pending as on 31stMarch, 2011.

Compliance Officer

Mr. Jayapal. K

69/C, GIDC Industrial Estate,

Vapi – 396 195, Dist. Valsad,

Gujarat, India

CERTIFICATE ON CORPORATE GOVERNANCE

To,

The Members,

Gujarat Themis Biosyn Limited

I have examined the compliance of conditions of Corporate Governance by the GujaratThemis Biosyn Limited for the year ended on 31st March, 2011 as stipulated in clause 49 ofthe listing agreement of the said Company with the stock exchanges.

The compliance of conditions of Corporate Governance is the responsibility of themanagement. My examination was limited to the procedures and implementations thereofadopted by the Company for ensuring the compliance of conditions of the CorporateGovernance. It is neither an audit nor an expression of opinion on the financialstatements of the Company.

In my opinion and to the best of information and explanations provided to me, I certifythat the Company has complied with the conditions of Corporate Governance as stipulated inClause 49 of the above mentioned listing agreement.

Based on verification of the records of the Company and as certified by theCompany’s Registrar and Share Transfer Agent, I state that no investor grievances arepending against the Company for more than 30 days as on 31st March, 2011.

I further state that such compliance is neither an assurance as to the future viabilityof the Company nor efficiency or effectiveness with which the management has conducted theaffairs of the Company.

SANDHYA BORASE
Company Secretary
Date : 26th August, 2011 ACS 8353
Place : Mumbai C P 4563
   

Peer Comparison

Company Market Cap
(Rs. in Cr.)
P/E (TTM)
(x)
P/BV (TTM)
(x)
EV/EBIDTA
(x)
ROE
(%)
ROCE
(%)
D/E
(x)
Lupin 34,417.57 27.30 7.10 21.23 23.4 22.7 0.30
Divi's Lab. 13,374.56 21.87 5.24 13.41 27.3 34.1 0.02
Jubilant Life 2,431.71 30.90 1.31 21.18 3.1 6.4 1.43
Shilpa Medicare 747.01 14.92 2.56 9.34 16.3 18.0 0.19
Hikal 679.47 26.63 1.98 5.65 22.4 18.2 1.53
Elder Pharma 596.28 6.48 0.77 6.59 12.9 13.0 1.25
Dishman Pharma. 577.41 11.93 0.86 5.44 6.8 10.2 0.80
Vinati Organics 550.01 8.01 2.28 5.63 33.2 31.3 0.75
Shasun Pharma. 456.20 16.55 1.68 7.48 14.0 8.9 1.05
Orchid Chemicals 436.79 0.00 0.48 7.67 9.7 8.3 1.75
Nectar Lifesci. 375.48 4.38 0.43 6.25 9.7 11.2 1.22
Sequent Scien. 340.05 0.00 2.23 7.62 -3.9 5.9 1.58
Suven Life Scie. 304.26 9.87 1.97 10.21 11.3 9.1 0.64
Granules India 278.50 9.23 1.03 4.12 11.7 15.2 0.57
Aarti Drugs 266.54 5.85 1.28 4.78 13.5 13.7 1.48

Futures & Options Quote

 
Expiry Date
NA
Instrument: NA
Expiry Date: NA
Strike Price: NA
Open Price: NA
Average Price: NA
No. of Contracts Traded: NA
Open Interest: NA
Underlying: NA
Option Type: NA
Market Lot: NA
Previous Close: NA
Day’s High | Low: NA | NA
Turnover (Cr.): NA
Open Int. Change: NA | NA
View detailed F& O quotes >>

Key Information

Key Executives:

Dinesh S Patel , Chairman 

A B Shah , Nominee (GIIC) 

Sachin D Patel , Director 

Vijay Agarwal , Director 


Company Head Office / Quarters:
69/C GIDC Industrial Estate,
Valsad Dist,
VAPI,
Gujarat-396195
Phone : 91-260-2430027
Fax : 91-260-2400639
E-mail : gtblmumbai@gtbl.in
Web : http://
Registrars:
Link Intime India Pvt Ltd
C-13 Pannalal Silk
Mills Cmpd LBS Marg
Bhandup West
Mumbai - 400 078

Fund Holding

 
Scheme Name No. of Shares
No data found

Calendar

May-2013
M T W T F S S
20 21 22 23 24 25 26
IPO
listIssue Open : Just Dial
listIssue Closing : Onesource Techm.
Economic Events
list Adjusted Merchandise Trade Balance (Yen)
list Merchandise Trade Balance Total (Yen)
Results
list Tech Mahindra